BACKGROUND: A trial of neoadjuvant gemcitabine and pemetrexed (GP) chemotherapy in patients with resectable non-small cell lung cancer was conducted. The goal was to achieve a disease response rate of 50% and to determine if the expression levels of genes associated with GP metabolism are predictive of response. METHODS: Patients had staging with a computed tomography scan, whole body F-18 fluorodeoxyglucose positron emission tomography, and mediastinoscopy. Four biweekly cycles of GP were given. Patients were restaged, and those with resectable stage IB-III disease had thoracotomy. Fresh frozen tumor specimens were collected before and after chemotherapy and the mRNA levels of 14 target genes determined by real-time reverse transcription polymerase chain reaction. RESULTS: Fifty-two patients started therapy. The radiographic disease response rate was 35% (95% confidence interval 21.7-49.6%), and the progression rate was 6%. Forty-six patients had a thoracotomy. The complete tumor resection rate was 77% (40/52). There were no perioperative deaths or deaths related to chemotherapy. Tumor response to chemotherapy was inversely correlated with the level of expression of RRM1 (p < 0.001; regulatory subunit of ribonucleotide reductase) and TS (p = 0.006; thymidylate synthase); i.e., the reduction in tumor size was greater in those with low levels of expression. CONCLUSIONS: Neoadjuvant GP is well tolerated and produces an objective response rate of 35%. Tumoral RRM1 and TS mRNA levels are predictive of disease response and should be considered as parameters for treatment selection in future trials with this regimen.
BACKGROUND: A trial of neoadjuvant gemcitabine and pemetrexed (GP) chemotherapy in patients with resectable non-small cell lung cancer was conducted. The goal was to achieve a disease response rate of 50% and to determine if the expression levels of genes associated with GP metabolism are predictive of response. METHODS:Patients had staging with a computed tomography scan, whole body F-18 fluorodeoxyglucose positron emission tomography, and mediastinoscopy. Four biweekly cycles of GP were given. Patients were restaged, and those with resectable stage IB-III disease had thoracotomy. Fresh frozen tumor specimens were collected before and after chemotherapy and the mRNA levels of 14 target genes determined by real-time reverse transcription polymerase chain reaction. RESULTS: Fifty-two patients started therapy. The radiographic disease response rate was 35% (95% confidence interval 21.7-49.6%), and the progression rate was 6%. Forty-six patients had a thoracotomy. The complete tumor resection rate was 77% (40/52). There were no perioperative deaths or deaths related to chemotherapy. Tumor response to chemotherapy was inversely correlated with the level of expression of RRM1 (p < 0.001; regulatory subunit of ribonucleotide reductase) and TS (p = 0.006; thymidylate synthase); i.e., the reduction in tumor size was greater in those with low levels of expression. CONCLUSIONS:Neoadjuvant GP is well tolerated and produces an objective response rate of 35%. TumoralRRM1 and TS mRNA levels are predictive of disease response and should be considered as parameters for treatment selection in future trials with this regimen.
Authors: Cynthia X Ma; Suresh Nair; Sachdev Thomas; Sumithra J Mandrekar; Daniel A Nikcevich; Kendrith M Rowland; Tom R Fitch; Harold E Windschitl; Shauna L Hillman; Steven E Schild; James R Jett; Coleman Obasaju; Alex A Adjei Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd Journal: N Engl J Med Date: 2005-06-23 Impact factor: 91.245
Authors: J A Roth; F Fossella; R Komaki; M B Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; M McGavran Journal: J Natl Cancer Inst Date: 1994-05-04 Impact factor: 13.506
Authors: R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal Journal: N Engl J Med Date: 1994-01-20 Impact factor: 91.245
Authors: Arkadiusz Z Dudek; Timothy Larson; Michael J McCleod; Daniel J Schneider; Jonathan E Dowell; Tarit K Banerjee; Kishan J Pandya; Jane L Bromund; Ruqin Chen; Matthew J Monberg; Coleman K Obasaju Journal: J Thorac Oncol Date: 2008-04 Impact factor: 15.609
Authors: T Masuda; H Imai; T Kuwako; Y Miura; R Yoshino; K Kaira; K Shimizu; N Sunaga; Y Tomizawa; S Ishihara; A Mogi; T Hisada; K Minato; A Takise; R Saito; M Yamada Journal: Clin Transl Oncol Date: 2015-05-20 Impact factor: 3.405
Authors: Shirish M Gadgeel; Michele L Cote; Ann G Schwartz; Larry H Matherly; Antoinette Wozniak; Gerold Bepler Journal: Drug Resist Updat Date: 2010-11-03 Impact factor: 18.500
Authors: David O Azorsa; Irma M Gonzales; Gargi D Basu; Ashish Choudhary; Shilpi Arora; Kristen M Bisanz; Jeffrey A Kiefer; Meredith C Henderson; Jeffrey M Trent; Daniel D Von Hoff; Spyro Mousses Journal: J Transl Med Date: 2009-06-11 Impact factor: 5.531